Top 10 Blockbuster Drug Patents Expiring in 2025
1. ABILIFY MAINTENA KIT
Revenue: $15.5 Billion
Long-acting injectable antipsychotics are gaining popularity for treating schizophrenia, offering more consistent medication delivery. A leading drug in this category is Abilify Maintena from Otsuka Pharmaceutical, which generated impressive sales of around $15.5 billion in 2022. Abilify Maintena consists of aripiprazole in an extended release injectable suspension, dosed monthly for maintenance treatment of schizophrenia in adults. By providing steady levels of the drug, Abilify Maintena avoids daily pills and improves adherence. Since its approval in 2013, Abilify Maintena has become a prime choice for patients and doctors managing schizophrenia. Despite requiring in-office injections, the efficacy and convenience has driven strong revenue growth for Otsuka. With long-acting injectables gaining traction, Abilify Maintena is poised to continue dominating this growing antipsychotic market.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry |
|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | |||
| US8399469 | OTSUKA PHARM CO LTD | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2025
(9 months from now) |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8338427 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Mar, 2025
(6 months from now) |
2. BIKTARVY
Revenue: $10.4 Billion
The HIV market continues to see new and improved treatment options emerge, including Biktarvy from Gilead Sciences. Biktarvy is an oral fixed-dose combination tablet containing bictegravir, emtricitabine and tenofovir alafenamide. Approved in 2018, it has quickly become a leading and blockbuster HIV therapy, generating over $10.4 billion in sales in 2022. As a complete one-pill, once-daily regimen, Biktarvy offers a convenient and well-tolerated treatment option for HIV patients. Clinical studies demonstrated Biktarvy's high efficacy with few side effects and high barriers to resistance. While not inexpensive, Biktarvy's profile as a simple, effective and durable HIV treatment has led to its adoption as a first-line therapy. With continued growth expected, Biktarvy is likely to remain an important blockbuster franchise for Gilead.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry |
|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | |||
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(7 months from now) |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(1 year, 1 month from now) |
3. COMBOGESIC
Revenue: $9.8 Billion
Combogesic is a blockbuster combination pain medication containing paracetamol (acetaminophen) and ibuprofen. Marketed by various pharmaceutical companies around the world, Combogesic generated estimated total sales of $9.8 billion in 2022. By combining two common analgesic ingredients, Combogesic provides a synergistic effect for relief of acute pain like headaches, muscle aches, backaches, arthritis, and toothaches. The convenience of a single tablet appeals to many consumers seeking an accessible over-the-counter option for pain relief without side effects like opioid medications. While paracetamol and ibuprofen are available generically, the popularity of the combined Combogesic brand has driven its commercial success as a blockbuster. However, some formulations also contain caffeine, requiring caution in certain individuals. Overall, Combogesic's simple yet effective approach to pain relief has made it a popular consumer healthcare blockbuster product worldwide.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10532036 | AFT PHARMS LTD | Combination composition |
Sep, 2025
(1 year, 13 days from now) |
4. XARELTO
Revenue: $4.5 Billion
Blood thinners are big business, with the anticoagulant drug market expected to reach $10 billion by 2024. One of the top-selling drugs in this category is Xarelto, developed by Janssen Pharms. Xarelto (rivaroxaban) is an oral direct factor Xa inhibitor that is used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is also used for preventing deep vein thrombosis which may lead to pulmonary embolism following knee or hip replacement surgery. While hugely successful, Xarelto has faced lawsuits over allegations of severe and sometimes fatal bleeding events. However, it remains a blockbuster drug for Janssen. With its patent expiring in the next few years, it will be interesting to see if lower-cost generics can compete with this blood thinner giant.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US7157456 (Pediatric) | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Feb, 2025
(5 months from now) |
|
US9415053 (Pediatric) | JANSSEN PHARMS | Solid, orally administrable pharmaceutical composition |
May, 2025
(8 months from now) |
5. FARXIGA
Revenue: $4.3 Billion
Diabetes medications are a major market, with new drug classes like SGLT2 inhibitors generating billions in sales. One of the top drugs in this class is Farxiga, developed by pharmaceutical giant AstraZeneca. Farxiga (dapagliflozin) is an oral SGLT2 inhibitor used for improving glycemic control in adults with type 2 diabetes, both as monotherapy and as an add-on treatment. By preventing glucose reabsorption in the kidneys, Farxiga causes excess glucose to be eliminated through urination. This provides substantial and sustained reductions in blood glucose levels. Since its launch, Farxiga has become a blockbuster diabetes drug for AstraZeneca, generating annual sales of around $4.3 billion, though it does come with side effects like urinary tract infections. As the diabetes epidemic grows worldwide, Farxiga is well-positioned to continue generating significant revenue.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry |
|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | |||
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(1 year, 25 days from now) |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(7 months from now) |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(7 months from now) |
| US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(9 months from now) |
|
US8461105 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 1 month from now) |
|
US8431685 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 1 month from now) |
|
US7456254 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Dec, 2025
(1 year, 3 months from now) |
6. OZEMPIC
Revenue: $3.6 Billion
The incretin mimetic class of diabetes medications continues to see substantial growth, driven by new GLP-1 receptor agonists like Ozempic from Novo Nordisk. Ozempic (semaglutide) is an injectable GLP-1 analogue used for improving glycemic control in type 2 diabetes patients. By mimicking the effects of the hormone GLP-1, Ozempic stimulates insulin release and suppresses glucagon secretion in a glucose-dependent manner. Since its approval in 2017, Ozempic has rapidly become a blockbuster diabetes drug for Novo Nordisk, generating annual sales of around $3.6 billion. However, it does require daily or weekly injection and has side effects like nausea. Still, with the growing diabetes population and strong efficacy, Ozempic is poised for continued commercial success for Novo Nordisk.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(11 months from now) |
| US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(1 year, 1 month from now) |
| US11446443 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(1 year, 1 month from now) |
7. OXYCONTIN
Revenue: $3 Billion
OxyContin (oxycodone controlled-release) is a powerful prescription opioid painkiller manufactured and marketed by Purdue Pharma. First approved in 1995, OxyContin generated over $3 billion in annual sales at its peak, making it the top-selling opioid painkiller in the U.S. However, OxyContin has also been at the center of the prescription opioid addiction epidemic, with Purdue Pharma paying out billions in legal settlements over allegations of deceptive marketing practices. While still available today for severe pain when alternative treatments are inadequate, OxyContin prescriptions have declined sharply in recent years as restrictions have tightened and public awareness of opioid addiction risks has grown. The story of OxyContin provides a cautionary tale about the pharmaceutical industry's pursuit of blockbuster profits and the tragic human consequences that can result.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry |
|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | |||
| US9073933 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(6 months from now) |
| US10407434 | PURDUE PHARMA LP | Process for preparing oxycodone compositions |
Mar, 2025
(6 months from now) |
| US9522919 | PURDUE PHARMA LP | Oxycodone compositions |
Mar, 2025
(6 months from now) |
| US10696684 | PURDUE PHARMA LP | Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(6 months from now) |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7683072 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(6 months from now) |
| US7674799 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone |
Mar, 2025
(6 months from now) |
| US7674800 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(6 months from now) |
| US7776314 | PURDUE PHARMA LP | Abuse-proofed dosage system |
Apr, 2025
(7 months from now) |
8. SYMBICORT
Revenue: $2.5 Billion
Respiratory diseases like asthma and COPD represent a significant market for pharmaceutical companies. A leading drug in this category is Symbicort from AstraZeneca, which generated sales of around $2.5 billion last year. Symbicort contains two active ingredients - budesonide, an inhaled corticosteroid, and formoterol, a long-acting beta2-agonist bronchodilator. By combining both ingredients, Symbicort provides effective anti-inflammatory and bronchodilator effects in a single inhaler for patients with asthma or COPD. Since its approval in 2006, Symbicort has become one of AstraZeneca's most successful respiratory drugs. Its ability to improve symptoms and reduce exacerbations has made it a go-to maintenance therapy for many patients. While cheap generic versions are now available, Symbicort remains a billion-dollar blockbuster franchise for AstraZeneca.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US8875699 (Pediatric) | ASTRAZENECA | Inhaler cap strap |
May, 2025
(7 months from now) |
9. ENTRESTO
Revenue: $2.5 Billion
Heart failure is a major health concern, with few recent blockbuster drugs emerging. One exception is Entresto from Novartis, which generated impressive sales of around $2.5 billion in 2022. Entresto (sacubitril/valsartan) is an oral combination drug used for reducing the risk of cardiovascular death and hospitalization in patients with chronic heart failure. By enhancing the protective neurohormonal systems while suppressing the harmful effects, Entresto helps improve outcomes. Since its FDA approval in 2015, Entresto has become a blockbuster heart failure drug for Novartis. Its ability to significantly reduce heart failure hospitalizations compared to older drugs like ACE inhibitors has driven its commercial success. With an aging population and rising prevalence of heart failure, Entresto is positioned to continue generating robust revenue growth for Novartis.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8101659 | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jan, 2025
(4 months from now) |
|
US8101659 (Pediatric) | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jul, 2025
(10 months from now) |
10. GENVOYA
Revenue: $2.3 Billion
Genvoya is a blockbuster HIV combination drug marketed by Gilead Sciences. In 2022, this fixed-dose tablet generated revenue of around $2.3 billion. Approved in 2015, Genvoya contains elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide, providing a complete HIV treatment regimen in one pill taken once daily. Compared to older HIV regimens, Genvoya offers improved efficacy, tolerability, and higher barriers to resistance. Its convenience and favorable safety profile has made Genvoya a recommended first-line treatment option for HIV. Despite availability of generic component drugs, Genvoya's popularity as a branded, single-tablet regimen continues to drive its commercial success as a leading blockbuster HIV therapy for Gilead. However, the company faces market share competition from other potent and well-tolerated HIV combination products.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry |
|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | |||
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(7 months from now) |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(1 year, 1 month from now) |